Thesis TrackerLoading companies…
All companies
Loading…
Thesis TrackerThesis TrackerLoading…
PYC Therapeutics (ASX:PYC), an RNA drug developer, is well funded as it approaches key clinical readouts. In August 2026, LSN Capital Partners highlighted PYC's fully funded four-program rare disease pipeline, encouraging clinical data and lower-than-expected R&D spending extending its funding runway. Firetrail noted the shares rose 25% in June after Cantor Fitzgerald initiated US analyst coverage as its polycystic kidney disease asset PYC-003 nears critical readouts, while Salter Brothers said a raise of about $653 million lifted cash to around $750 million, funding the company to roughly 2030. PYC Therapeutics operates in the Healthcare sector within the Biotechnology industry, and Thesis Tracker has captured 16 comments from 3 fund managers, LSN, Firetrail and Salter Brothers. Founded in 2001 and headquartered in Nedlands, Perth, PYC develops precision RNA therapeutics for genetic diseases, including inherited blindness and polycystic kidney disease.
Company figures as of 15 Oct 2026. For information only.
Fund managers including Salter Brothers, Firetrail Investments and LSN Capital Partners have invested in PYC Therapeutics Ltd (ASX:PYC).
Managers highlight a fully funded pipeline with cash of around $750 million, upcoming clinical readouts for PYC-003 in polycystic kidney disease and blindness therapies, new US analyst coverage and lower-than-expected spending, according to LSN, Firetrail and Salter Brothers.
Firetrail notes the shares underperformed during market risk-off periods, and as a clinical-stage company PYC's value depends on positive trial outcomes and regulatory approvals.
PYC Therapeutics Ltd. is an Australian drug-development company headquartered in Nedlands. Founded in 2001 by Richmond Miles Hopkins and Paul Michael Watt, the company specializes in RNA therapeutics designed to address unmet medical needs. PYC Therapeutics utilizes its proprietary cell-penetrating Phylomers platform to develop intracellular biological therapeutics, including a portfolio of preclinical oncology payloads. The firm focuses on advancing next-generation RNA therapies through its specialized delivery technology.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.